News

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.
In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...
A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...
Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three ...
Cantor Fitzgerald cut Eli Lilly’s FY2025 earnings forecast from $21.91 to $21.76 per share. Eli Lilly reported $3.34 per ...
A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, ...
The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...
Caitlin Clark Makes Exciting Announcement on Thursday originally appeared on Athlon Sports. Indiana Fever point guard Caitlin ...
Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...
Obesity medications, once facing shortages, are now widely available. So how do consumers not get scammed into purchasing ...
Eli Lilly’s stock closed at $786.92, marking a 1.19% gain, outpacing the broader market. Despite a 3.66% drop in the past ...
At last year’s inaugural “Famous Hoosiers” program Richard Gunderman made a moving and very well received presentation about Hoosier legend John Wooden. This year, Gunderman, chancellor’s professor in ...